Jim Cramer Says Merck & Co., Inc. (MRK) ‘Needs To Have China Be Less Of Our Enemy’
We recently published an article titled Jim Cramer Discusses These 18 Stocks & President Trump’s $500 Billion AI Plan. In ...
Merck & Co. Inc. stock underperforms Friday when compared to competitors
Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.
Here’s Why Merck & Co., Inc. (MRK) Is Among the Highest Yielding Dividend Stocks In the Dow
We recently compiled a list of the 13 Highest Yielding Dividend Stocks in the Dow. In this article, we are going to take a ...
Kennedy would keep legal fees from Merck cases if confirmed
Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...
Why Is Merck & Co., Inc. (MRK) Among the Best Large-Cap Value Stocks to Buy in 2025?
We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...
Merck's SWOT analysis: stock outlook amid oncology competition, pipeline growth
Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...
FiercePharma2d
Merck, Eisai's star-crossed Keytruda-Lenvima combo misses survival goal in GI cancer trial
Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...
Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK)
In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...
Is Merck & Co., Inc. (MRK) the Most Reliable Dividend Stock to Buy According to Hedge Funds?
We recently compiled a list of the 12 Most Reliable Dividend Stocks To Buy According to Hedge Funds. In this article, we are ...
Merck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer Study
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.
Jim Cramer on Merck & Co., Inc. (MRK): ‘Right Now, The Stock’s Well-ensconced A Few Points Around 52-week Low’
We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Merck & Co., Inc.
Merck & Co.’s Accelerated Keytruda Launch and Strategic Updates Bolster Long-term Growth Prospects
Analyst Akash Tewari of Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), retaining the price target of ...